|
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
1 |
[GO] |
2025―Jan―17 |
Corrigendum to “Natural fucoidans inhibit coronaviruses by targeting viral spike protein and host cell furin” [Biochem. Pharmacol. 215 (2023) 115688] |
Cheng-Wei Yang, Hsing-Yu Hsu, Yue-Zhi Lee, Jia-Tsrong Jan, Sui-Yuan Chang, Yi-Ling Lin, et al. (+10) Ruey-Bing Yang, Tai-Ling Chao, Jian-Jong Liang, Shu-Jing Lin, Chun-Che Liao, Chih-Shin Chang, Huey-Kang Sytwu, Ming-Shiu Hung, Chiung-Tong Chen, Shiow-Ju Lee |
2 |
[GO] |
2024―Jun―22 |
Takotsubo syndrome as an outcome of the use of checkpoint inhibitor therapy in patients with COVID-19 |
Júlia Leão Batista Simões, Geórgia de Carvalho Braga, João Victor Coiado, Alexandre Bachietti Scaramussa, Ana Paula Barasuol Rodrigues, Margarete Dulce Bagatini |
3 |
[GO] |
2024―Feb―17 |
Developing CAR-immune cell therapy against SARS-COV-2: Current status, challenges, and prospects |
Yizhao Chen, Chong Liu, Yilong Fang, Weile Chen, Jiaqi Qiu, Mengjuan Zhu, et al. (+2) Wei Wei, Jiajie Tu |
4 |
[GO] |
2023―Dez―09 |
Bile acids and bile acid activated receptors in the treatment of Covid-19 |
Stefano Fiorucci, Ginevra Urbani, Michele Biagioli, Valentina Sepe, Eleonora Distrutti, Angela Zampella |
5 |
[GO] |
2023―Jul―21 |
Natural fucoidans inhibit coronaviruses by targeting viral spike protein and host cell furin |
Cheng-Wei Yang, Hsing-Yu Hsu, Yue-Zhi Lee, Jia-Tsrong Jan, Sui-Yuan Chang, Yi-Ling Lin, et al. (+10) Ruey-Bing Yang, Tai-Ling Chao, Jian-Jong Liang, Shu-Jing Lin, Chun-Che Liao, Chih-Shin Chang, Huey-Kang Sytwu, Ming-Shiu Hung, Chiung-Tong Chen, Shiow-Ju Lee |
6 |
[GO] |
2023―Jan―30 |
Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators |
Nusrath Yasmeen, S. Harikrishnan, Sudarshan S Lakhawat, Manali Datta, Pushpender K Sharma, Ajay Jain, et al. (+3) Rakhi Khanna, S Jayalakshmi, Vikram Kumar |
7 |
[GO] |
2022―Dez―30 |
Applications of Nanobodies in the Prevention, Detection, and Treatment of the Evolving SARS-CoV-2 |
Wenyi Wang, Yue Hu, Bohan Li, Huanan Wang, Jinhua Shen |
8 |
[GO] |
2022―Dez―05 |
Counter-regulatory renin-angiotensin system in hypertension: review and update in the era of COVID-19 pandemic |
Hongyin Chen, Jiangyun Peng, Tengyao Wang, Jielu Wen, Sifan Chen, Yu Huang, Yang Zhang |
9 |
[GO] |
2022―Okt―31 |
Glycosylation in SARS-CoV-2 Variants: A path to Infection and Recovery |
Arya Aloor, Rajaguru Aradhya, Parvathy Venugopal, Bipin Gopalakrishnan Nair, Renuka Suravajhala |
10 |
[GO] |
2022―Okt―06 |
An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges |
Xiaoying Xu, Yuheng Chen, Xinyu Lu, Wanlin Zhang, Wenxiu Fang, Luping Yuan, Xiaoyan Wang |
11 |
[GO] |
2022―Jul―03 |
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19 |
Jin Huang, Chi Zhou, Jinniu Deng, Jianfeng Zhou |
12 |
[GO] |
2021―Nov―18 |
The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders |
Upasana Parthasarathy, Roberta Martinelli, Elisabeth H. Vollmann, Katharine Best, Alex G. Therien |
13 |
[GO] |
2021―Aug―08 |
Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2) |
Yusen Xiang, Mengge Wang, Hongzhuan Chen, Lili Chen |
14 |
[GO] |
2021―Apr―02 |
Animal Models for SARS-Cov2/Covid19 Research-A Commentary |
Kurt Jarnagin, Oscar Alvarez, Sujan Shresta, David R Webb |
15 |
[GO] |
2021―Feb―10 |
Sleep during COVID-19 lockdown: A cross-cultural study investigating job system relevance |
Cristina Florea, Pavlos Topalidis, Theresa Hauser, Monika Angerer, Anton Kurapov, Carlos Alberto Beltran Leon, et al. (+2) Daniel Soares Brandão, Manuel Schabus |
16 |
[GO] |
2021―Jan―28 |
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking |
Claire Lugnier, Hayder M. AL-Kuraishi, Eric Rousseau |
17 |
[GO] |
2021―Jan―19 |
Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics |
Li Zeng, Dongying Li, Weida Tong, Tieliu Shi, Baitang Ning |
18 |
[GO] |
2020―Okt―27 |
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro |
Junke Song, Li Zhang, Yanfeng Xu, Dezhi Yang, Li Zhang, Shiying Yang, et al. (+13) Wen Zhang, Jinhua Wang, Shuo Tian, Shengqian Yang, Tianyi Yuan, Ailin Liu, Qi Lu, Fengdi Li, Hongqi Liu, Biyu Hou, Xiaozhong Peng, Yang Lu, Guanhua Du |
19 |
[GO] |
2020―Okt―22 |
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action |
Hassan Yousefi, Ladan Mashouri, Samuel C. Okpechi, Nikhilesh Alahari, Suresh K. Alahari |
20 |
[GO] |
2020―Okt―04 |
Corrigendum to “Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost” [Biochem. Pharmacol. 178 (2020) 114057] |
Manar Mohammed El Tabaa, Maram Mohammed El Tabaa |
21 |
[GO] |
2020―Sep―20 |
AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication |
Jonathan O. Rayner, Rosemary A. Roberts, Jin Kim, Andrew Poklepovic, Jane L. Roberts, Laurence Booth, Paul Dent |
22 |
[GO] |
2020―Sep―19 |
Role of Proteolytic Enzymes In the Covid-19 Infection And Promising Therapeutic Approaches |
Magda Gioia, Chiara Ciaccio, Paolo calligari, Giovanna De Simone, Diego sbardella, Grazia tundo, et al. (+6) Giovanni Francesco Fasciglione, Alessandra di Masi, Donato Di Pierro, Alessio Bocedi, Paolo Ascenzi, Massimo Coletta |
23 |
[GO] |
2020―Sep―06 |
The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations |
Meik Neufurth, Xiaohong Wang, Emad Tolba, Ingo Lieberwirth, Shunfeng Wang, Heinz C. Schröder, Werner E.G. Müller |
24 |
[GO] |
2020―Jul―30 |
COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials |
Rohan Chakraborty, Suhel Parvez |
25 |
[GO] |
2020―Jul―23 |
Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2 |
Lucia Lisi, Pedro Miguel Lacal, Maria Luisa Barbaccia, Grazia Graziani |
26 |
[GO] |
2020―Jun―25 |
Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction |
Gary Williamson, Asimina Kerimi |
27 |
[GO] |
2020―Jun―21 |
SARS-CoV-2 and Cardiovascular Complications: from Molecular Mechanisms to Pharmaceutical Management |
Lin Wu, Aislinn M. O'Kane, Hu Peng, Yaguang Bi, Dagmara Motriuk-Smith, Jun Ren |
28 |
[GO] |
2020―Mai―27 |
Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost |
Manar Mohammed El Tabaa, Maram Mohammed El Tabaa |